US 7989425B2
· Sung et al.
· 2011
[cited by applicant]
US 8673319B2
· Colloca et al.
· 2014
[cited by applicant]
US 9133483B2
· Wilson et al.
· 2015
[cited by applicant]
US 9359618B2
· Roy et al.
· 2016
[cited by applicant]
US 9593346B2
· Roy et al.
· 2017
[cited by applicant]
US 9597363B2
· Roy et al.
· 2017
[cited by applicant]
US 9617561B2
· Roy et al.
· 2017
[cited by applicant]
EP 2325298B2
· 2011
[cited by applicant]
WO 2009073103A2
· 2009
[cited by applicant]
WO WO2010051367A1
· 2010
[cited by examiner]
WO 2010138675A1
· 2010
[cited by applicant]
WO 2012024351A2
· 2012
[cited by applicant]
WO 2019086450A1
· 2019
[cited by applicant]
WO 2019086456A1
· 2019
[cited by applicant]
WO 2019086461
· 2019
[cited by applicant]
WO 2019086466A1
· 2019
[cited by applicant]
Rux et al. (2004) “Adenovirus structure” Human gene therapy, 15(12), 1167-1176. (Year: 2004).
[cited by examiner]
Bots et al. (2022) “Nonhuman primate adenoviruses of the human adenovirus B species are potent and broadly acting oncolytic vector candidates” Human Gene Therapy, 33(5-6), 275-289. (Year: 2022).
[cited by examiner]
Office Action for European Patent Application No. 20740097.9 (Dated Sep. 15, 2023).
[cited by applicant]
International Search Report and Written Opinion for corresponding Application No. PCT/NL2020/050443 (mailed Nov. 2, 2020).
[cited by applicant]
Cheng et al., “A Novel Oncolytic Adenovirus Based on Simian Adenovirus Serotype 24,” Oncotarget 8 (16):26871-26885 (2017).
[cited by applicant]
Chiu, J et al: “Site-directed, Ligase-Independent Mutagenesis (SLIM): A Single-tube Methodology Approaching 100% Efficiency in 4 h,” Nucleic Acids Res 32(21):e174 (2004).
[cited by applicant]
Arnberg et al., “Adenovirus Type 37 Uses Sialic Acid as a Cellular Receptor on Chang C Cells.” Journal of Virology, 76(17):8834-8841 (2002).
[cited by applicant]
Arnberg, Niklas “Adenovirus Receptors: Implications for Tropism, Treatment and Targeting,” Reviews in Medical Virology 25(1):2-23 (2015).
[cited by applicant]
Barnadas et al., “Molecular Epidemiology of Human Adenovirus Infections in Denmark, 2011-2016,” Journal of Clinical Virology 104:16-22 (2018).
[cited by applicant]
Bauer et al., “Detection of Antibodies Against Adenovirus Protein IX, Fiber, and Hexon in Human Sera by Immunoblot Assay,” Journal of Clinical Microbiology 43(9):4426-4433 (2005).
[cited by applicant]
Cappuccini et al., “Immunogenicity and Efficacy of the Novel Cancer Vaccine Based on Simian Adenovirus and MVA Vectors Alone and in Combination With PD-1 mAb in a Mouse Model of Prostate Cancer,” Cancer Immunology, Immu…
[cited by applicant]
Cervera-Carrascon et al., “TNFa and IL-2 Armed Adenoviruses Enable Complete Responses by Anti-PD-1 Checkpoint Blockade,” OncoImmunology 7(5):1-11 (2018).
[cited by applicant]
Engeland et al., “CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy,” Molecular Therapy 22(11): 1949-1959 (2014).
[cited by applicant]
Filley and Dey, “Immune System, Friend or Foe of Oncolytic Virotherapy?” Frontiers in Oncology 7:1-8 (2017).
[cited by applicant]
Gaggar et al., “CD46 is a cellular receptor for group B adenoviruses,” Nature Medicine, 9(11), 1408-1412 (2003).
[cited by applicant]
Grekova et al., “Activation of a Glioma-specific Immune Response by Oncolytic Parvovirus Minute Virus of Mice Infection,” Cancer Gene Therapy 19(7):468-475 (2012).
[cited by applicant]
Grossardt et al., “Granulocyte-Macrophage Colony-Stimulating Factor-Armed Oncolytic Measles Virus Is an Effective Therapeutic Cancer Vaccine,” Human Gene Therapy 24(7):644-654 (2013).
[cited by applicant]
Heise et al., “ONYX-015, an EIB Gene-attenuated Adenovirus, Causes Tumor-specific Cytolysis and Antitumoral Efficacy That Can be Augmented by Standard Chemotherapeutic Agents,” Nature Medicine (44):398-399 (1997).
[cited by applicant]
Hoppe et al., “Multiple Cross-species Transmission Events of Human Adenoviruses (HAdV) During Hominine Evolution,” Molecular Biology and Evolution 32(8):2072-2084 (2015).
[cited by applicant]
Kaufman et al., “Oncolytic Viruses: A New Class of Immunotherapy Drugs,” Nature Reviews Drug Discovery 14(9):642-662 (2015).
[cited by applicant]
Kleijn et al., “The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD is Mediated by Tumor-specific Immunity,” PLoS ONE 9(5):e97495 (2014).
[cited by applicant]
Larson et al., “Going Viral: A Review of Replication-selective Oncolytic Adenoviruses,” Oncotarget 6(24):19976-89 (2015).
[cited by applicant]
Lion et al., “Adenovirus Infections in Immunocompetent and Immunocompromised Patients,” Clinical Microbiology Reviews 27(3):441-462 (2014).
[cited by applicant]
Lynch et al., “Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention,” Seminars in Respiratory and Critical Care Medicine 37(4):586-602 (2016).
[cited by applicant]
Madisch et al., “Phylogenetic Analysis and Structural Predictions of Human Adenovirus Penton Proteins as a Basis for Tissue-Specific Adenovirus Vector Design,” Journal of Virology 81(15):8270-8281 (2007).
[cited by applicant]
Martin et al., “Pre-surgical Neoadjuvant Oncolytic Virotherapy Confers Protection Against Rechallenge in a Murine Model of Breast Cancer,” Scientific Reports 9(1):1865 (2019).
[cited by applicant]
Mostafa et al., “Oncolytic Reovirus And Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer,” Cancers 10(6):1-18 (2018).
[cited by applicant]
Pantó et al., “Taxonomy Proposal for Old World Monkey Adenoviruses: Characterisation of Several Non-human, Non-ape Primate Adenovirus Lineages,” Archives of Virology 160(12):3165-3177 (2015).
[cited by applicant]
Raja et al., “Oncolytic Virus Immunotherapy: Future Prospects for Oncology,” Journal for ImmunoTherapy of Cancer 6(1):140 (2018).
[cited by applicant]
Shashkova et al., “Characterization of Human Adenovirus Serotypes 5, 6, 11, and 35 as Anticancer Agents,” Virology 394:311-320 (2009).
[cited by applicant]
Short et al., “Members of Adenovirus Species B Utilize CD80 and CD86 as Cellular Attachment Receptors,” Virus Research 122(1-2):144-153 (2006).
[cited by applicant]
Shtrichman and Kleinberger, “Adenovirus Type 5 E4 Open Reading Frame 4 Protein Induces Apoptosis in Transformed Cells Adenovirus Type 5 E4 Open Reading Frame 4 Protein Induces Apoptosis in Transformed Cells,” Journal of…
[cited by applicant]
Vogels et al., “Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity,” Journal of Virology,77(15):8263-82…
[cited by applicant]
Wang et al., “Desmoglein 2 is a Receptor for Adenovirus Serotypes 3, 7, 11, and 14,” Nature Medicine 17(1):96-104 (2011).
[cited by applicant]
Zhang et al., “Adenovirus Receptors,” Journal of Virology 79(19):12125-12131 (2005).
[cited by applicant]
Zhao et al., “Seroprevalence of Neutralizing Antibodies Against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients,” Frontiers in Immunology 9:335 1-9 (2018).
[cited by applicant]
Thomas et al., “Immunosuppression Enhances Oncolytic Adenovirus Replication And Anti Tumor Efficacy in the Syrian Hamster Model,” Mol Ther. 16:1665-1673 (2008).
[cited by applicant]
Bredenbeek et al., “A Stable Full-length Yellow Fever Virus cDNA Clone and the Role of Conserved RNA Elements in Flavivirus Replication,” J Gen Virol 84:1261-1268 (2003).
[cited by applicant]
Hanahan et al., “Studies on Transformation of
[cited by applicant]
Kong et al. “An Efficient In Vivo Recombination Cloning Procedure for Modifying and Combining HSV-1 Cosmids,” J Virol Methods 80(2):129-136 (1999).
[cited by applicant]
Fallaux et al., “Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1-deleted Adenoviral Vectors,” Hum Gene Ther 7(2):215-222 (1996).
[cited by applicant]
Stolarek et al., “Robust Infectivity and Replication of Delta-24 Adenovirus Induce Cell Death in Human Medulloblastoma,” Cancer Gene Ther 11:713-720 (2004).
[cited by applicant]
García-Nafría et al., “Iva Cloning: A Single-Tube Universal Cloning System Exploiting Bacterial in Vivo Assembly,” Sci Rep 6:27459 (2016).
[cited by applicant]
Whyte et al., “Two Regions of the Adenovirus Early Region 1A Proteins Are Required For Transformation.” J. Virol.62:257-265 (1988).
[cited by applicant]
Horwitz, M.S., “Function of Adenovirus E3 Proteins and Their Interactions With Immunoregulatory Cell Proteins,” J Gene Med 6:S172-S183 (2004).
[cited by applicant]
Suzuki et al., “The Presence of the Adenovirus E3 Region Improves the Oncolytic Potency of Conditionally Replicative Adenoviruses,” Clin. Cancer Res. 8:3348-3359 (2002).
[cited by applicant]
Singh et al., “Homologous Recombination in E3 Genes of Human Adenovirus Species D,” J Virol. 87:12481-12488 (2013).
[cited by applicant]
Bagchi et al., “The Retinoblastoma Protein Copurifies With E2F-I, an E1A-regulated Inhibitor of the Transcription Factor E2F,” Cell 65:1063-72 (1991).
[cited by applicant]
Bandara et al., “Adenovirus E1a Prevents the Retinoblastoma Gene Product From Complexing With a Cellular Transcription Factor,” Nature 351:494-497 (1991).
[cited by applicant]
Chellappan et al., “Adenovirus E1A, Simian Virus 40 Tumor Antigen, and Human Papillomavirus E7 Protein Share the Capacity to Disrupt the Interaction Between Transcription Factor E2F and the Retinoblastoma Gene Product,”…
[cited by applicant]
Avvakumov et al., “Comprehensive Sequence Analysis of the E1A Proteins of Human and Simian Adenoviruses,” Virology 329:477-492 (2004).
[cited by applicant]
Fueyo et al., “A Mutant Oncolytic Adenovirus Targeting the Rb Pathway Produces Anti-glioma Effect In Vivo,” Oncogene 19(1):2-12 (2000).
[cited by applicant]
Whyte et al., “Cellular Targets for Transformation by the Adenovirus E1A Proteins,” Cell 56:67-75 (1989).
[cited by applicant]
Examination Report issued for Australian Patent Application No. 2020310037, dated Feb. 28, 2025.
[cited by applicant]
Roy et al., “Complete Nucleotide Sequences and Genome Organization of Four Chimpanzee Adenoviruses”, Virology 324:361-372 (2004).
[cited by applicant]
Roy et al., “Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors”, Human Gene Therapy 15:519-530 (2004).
[cited by applicant]
Roy et al., “Generation of an Adenoviral Vaccine Vector Based on Simian Adenovirus 21”, Journal of General Virology 87:2477-2485 (2006).
[cited by applicant]
Roy et al., “Isolation and Characterization of Adenoviruses Persistently Shed from the Gastrointestinal Tract of Non-Human Primates”, PLoS Pathogens 5(7):e1000503 (2009).
[cited by applicant]
Wevers et al., “A Novel Adenovirus of Western Lowland Gorillas (Gorilla gorilla gorilla),” Virology Journal 7 (303): 1-8 (2010).
[cited by applicant]
McVey et al., “Adenoviruses Isolated from Wild Gorillas Are Closely Related to Human Species C Viruses”, Virology 444:119-123 (2013).
[cited by applicant]
Malouli et al., “Full Genome Sequence Analysis of a Novel Adenovirus of Rhesus Macaque Origin Indicates a New Simian Adenovirus Type and Species”, Virol Rep 3-4:18-29 (2014).
[cited by applicant]
Uusi-Kerttula et al., “Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immune-Oncolytic Applications”, Viruses 7:6009-6042 (2015).
[cited by applicant]
Priority Search Report and Written Opinion for Application No. NL2023464 dated Feb. 20, 2020.
[cited by applicant]
International Preliminary Report on Patentability Application No. PCT/NL2020/050443 (mailed Jan. 20, 2022).
[cited by applicant]